First Barium-Based Contrast Agent Gets FDA Approval
Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved E-Z-HD (barium sulfate) for oral suspension for use in double-contrast radiographic examinations of the esophagus, stomach, and duodenum; to visualize the gastrointestinal (GI) tract in patients aged ≥12 years.
E-Z-HD is the first approval of a barium-based contrast agent in the United States. Barium sulfate, due to its high molecular density is opaque to x-rays and therefore, acts as a positive contrast agent for radiographic studies. Barium sulfate is biologically inert and therefore, is not absorbed or metabolized by the body and is eliminated unchanged from the body.
E-Z-HD for oral suspension will be available as a white powder in a single-dose bottle containing 340g of barium sulfate for reconstitution. It will be supplied as 24 bottles per pack.
For more information call (877) 272-2269 or visit BraccoImaging.com.